why choose us

First received: April 03, 2023

Clinical Trial: Everolimus Aging Study

Study Status: Completed

Recruit Status: RECRUITING

Condition: Aging

Study Type: INTERVENTIONAL


Official Title: Clinical Evaluation of mTORC1 Inhibition for Geroprotection

Brief Summary: The objective of this project is to determine if mTORC1 inhibition by 24 weeks of daily (0.5 mg/day) or weekly (5 mg/week) everolimus can safely improve physiological and molecular hallmarks of aging in humans.Participants who are 55-80 years old and insulin resistant or prediabetic will be randomized to treatment and can expect to be on study for up to approximately 38 weeks.Participants aged 18-35 will not receive the intervention and can expect to be on study for up to approximately 8 weeks.

Read more